Keywords: Boehringer Ingelheim, Priaxon, R&D collaboration, Cancer

Boehringer Ingelheim and Priaxon collaborate on novel treatments for cancer

Article | 19 January 2010

German independent drug major Boehringer Ingelheim has entered into a worldwide collaboration with fellow Germany-based drug developer Priaxon to research ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in